0.5(top 100%)
impact factor
2.5K(top 10%)
papers
17.7K(top 10%)
citations
47(top 20%)
h-index
0.6(top 100%)
impact factor
3.5K
all documents
18.5K
doc citations
81(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1VigiBase, the WHO Global ICSR Database System: Basic FactsDrug Information Journal2008398
2The Use of Biological Assays to Evaluate BotanicalsDrug Information Journal1998382
3Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory ProcessDrug Information Journal2002306
4Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working PartyDrug Information Journal1995232
5The Application of the Principle of Intention–to–Treat to the Analysis of Clinical TrialsDrug Information Journal1991206
6Type I Error Rates from Mixed Effects Model Repeated Measures Versus Fixed Effects Anova with Missing Values Imputed Via Last Observation Carried ForwardDrug Information Journal2001129
7The Pursuit of Balance Using Stratified and Dynamic Randomization Techniques: An OverviewDrug Information Journal2003118
8Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and ExamplesDrug Information Journal2006114
9Adaptive Designs: Terminology and ClassificationDrug Information Journal2006114
10Statistical Considerations for Multiplicity in Confirmatory ProtocolsDrug Information Journal199697
11Quality Criteria and Standardization of Phytopharmaceuticals: Can Acceptable Drug Standards Be Achieved?Drug Information Journal199894
12Government Viewpoint of Clinical TrialsDrug Information Journal198290
13R&D Costs and Returns by Therapeutic CategoryDrug Information Journal200485
14Use of Fingerprinting and Marker Compounds for Identification and Standardization of Botanical Drugs: Strategies for Applying Pharmaceutical HPLC Analysis to Herbal ProductsDrug Information Journal199884
15Guidelines for Economic Evaluations in Italy: Recommendations from The Italian Group of Pharmacoeconomic StudiesDrug Information Journal200184
16Evaluation of Indian Traditional MedicineDrug Information Journal200181
17Some Issues in the Design and Analysis of Equivalence TrialsDrug Information Journal199980
18Sample Size Reestimation: A Review and RecommendationsDrug Information Journal200678
19Handling Missing Data in Clinical Trials: An OverviewDrug Information Journal200077
20Statistical Assessment of Mean Differences between Two Dissolution Data SetsDrug Information Journal199675
21Intent-to-Treat Analysis versus As-Treated AnalysisDrug Information Journal199673
22Flexible Sample Size Considerations Using Information-Based Interim MonitoringDrug Information Journal200170
23Innovation Deficit in the Pharmaceutical IndustryDrug Information Journal199667
24Design Issues in Noninferiority/Equivalence TrialsDrug Information Journal199967
25Effective Strategies for Maintaining Research Participation in Clinical TrialsDrug Information Journal200962
26Implementing Adaptive Designs: Logistical and Operational ConsiderationsDrug Information Journal200660
27In Vitro/In Vivo CorrelationsDrug Information Journal199558
28Risk Perception of Prescription Drugs: Results of a National SurveyDrug Information Journal200757
29Assessment of Consistency of Treatment Effects in Multiregional Clinical TrialsDrug Information Journal201056
30A Quantitative Approach for Making Go/No-Go Decisions in Drug DevelopmentDrug Information Journal201153
31On the Use of the Accelerated Failure Time Model As An Alternative to the Proportional Hazards Model in the Treatment of Time to Event Data: A Case Study in InfluenzaDrug Information Journal200252
32Public Health Care Management of Water Pollution with Pharmaceuticals: Environmental Classification and Analysis of Pharmaceutical Residues in Sewage WaterDrug Information Journal200552
33New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical FirmsDrug Information Journal200051
34Using Conjoint Analysis to Evaluate Health State PreferencesDrug Information Journal199950
35Interim Monitoring of Group Sequential Trials Using Spending Functions for the Type I and Type II Error ProbabilitiesDrug Information Journal200150
36Adaptive Dose-Response StudiesDrug Information Journal200650
37International Harmonization and Consensus DIA Meeting on Bioavailability and Bioequivalence Testing Requirements and StandardsDrug Information Journal199148
38Measuring the Incidence, Causes, and Repercussions of Protocol AmendmentsDrug Information Journal201148
39Cross-Cultural Comparability of Quality of Life MeasuresDrug Information Journal199346
40Nonparametric Analysis of Covariance and Its Role in Noninferiority Clinical TrialsDrug Information Journal199946
41Some Developments on the International Index of Erectile Function (IIEF)Drug Information Journal199945
42Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert TeamDrug Information Journal200545
43Confidentiality and Trial Integrity Issues for Adaptive DesignsDrug Information Journal200645
44Consequences of Delayed Treatment Effects on Analysis of Time-to-Event EndpointsDrug Information Journal200744
45Impact of Unrecognized Dosing Errors on the Cost and Effectiveness of PharmaceuticalsDrug Information Journal198842
46Summarizing Laboratory Data with Different Reference Ranges in Multi-Center Clinical TrialsDrug Information Journal199242
47Quantum of Effectiveness Evidence in FDA’s Approval of Orphan DrugsDrug Information Journal201241
48The International Register of Lithium BabiesDrug Information Journal197640
49Population Pharmacokinetics and Pharmacodynamics: An Underutilized ResourceDrug Information Journal199840
50One Large, Well-Designed, Multicenter Study as an Alternative to the Usual Fda ParadigmDrug Information Journal199939